米国におけるMA (メディカルアフェアーズ) 部門の評価：喘息/COPD
Medical Affairs Reputations (US) [Asthma/COPD]
|米国におけるMA (メディカルアフェアーズ) 部門の評価：喘息/COPD|
当レポートでは、喘息/COPDの治療薬主要12製品を取り扱う各社メディカルアフェアーズ (MA) チームについて米国の呼吸器科医および一般医100名を対象に調査し、各社チームのパフォーマンスおよび満足度に対するスコアリングおよびランキング、医師によるサービス利用の動向、要望、改善箇所の分析などをまとめています。
How well does your asthma/COPD medical affairs team performance compare with the rest?
According to this latest survey of 100 US pulmonologists and primary care physicians, the performance of asthma/COPD medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.
Use Medical Affairs Reputations: Asthma/COPD 2017 (US) to discover how your team can better meet the high expectations of physicians at the frontline.
This report compares the current activities of medical affairs teams for the 12 leading treatments for asthma/COPD from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, and Roche. It shows:
It's time to find out exactly how well your medical affairs team is performing against fierce competition - and establish an action plan to gain competitive advantage.
Interested in the European market? Click here to see the EU5 Edition.
Request sample pages
Insight into Medical affairs teams for these asthma/COPD treatments
A Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of medical affairs teams for 12 leading asthma/COPD brands-answering important questions like:
What do physicians need?
Does your medical affairs team deliver?
What needs improvement?
Based on Interviews with Practicing Doctors
We surveyed 100 US-based pulmonologists and primary care physicians, chosen from the largest community of validated physicians in the world.
We conducted the survey between August 1st and 16th, 2017.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
.FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.